Chen Xiaoyu, Liu Y Diana, Flynn Gregory C
Department of Analytical and Formulation Sciences, Amgen, Thousand Oaks, CA 91320, USA.
Glycobiology. 2009 Mar;19(3):240-9. doi: 10.1093/glycob/cwn120. Epub 2008 Oct 30.
Several studies using a variety of approaches have investigated the impact of the Fc glycan structure on IgG clearance rates. Most, but not all, of these studies have concluded that glycan structural differences do not affect clearance. Here we investigated the impact of glycan on the clearance of a human antibody in humans. To monitor glycan-dependent changes, a human IgG2 was affinity purified in a single step from serum samples from a human pharmacokinetic study. The glycan profile from the purified antibody samples was determined by RP-HPLC/MS analysis of the 2-aminobenzamide-labeled glycans. Relative levels of high-mannose species (M6-M9) decreased over circulation time. Differences in the individual high-mannose structural isoform clearance rates were measured from extracted ion current profiles. Similar changes to the glycan profile could be achieved through incubation of the antibody in serum in vitro, suggesting that the changes observed in vivo were the result of glycan cleavage, not differential antibody clearance. These results confirm that antibody clearance is not significantly affected by the Fc glycan structure and provide evidence for the presence of circulating mannosidase activity in humans.
多项采用各种方法的研究探讨了Fc聚糖结构对IgG清除率的影响。这些研究中的大多数(但并非全部)得出结论,聚糖结构差异不会影响清除率。在此,我们研究了聚糖对人源抗体在人体内清除的影响。为监测聚糖依赖性变化,从一项人体药代动力学研究的血清样本中一步亲和纯化出人IgG2。通过对2-氨基苯甲酰胺标记的聚糖进行RP-HPLC/MS分析,确定纯化抗体样本的聚糖谱。高甘露糖型(M6-M9)的相对水平随循环时间降低。从提取的离子电流图谱测量各个高甘露糖结构异构体清除率的差异。通过在体外血清中孵育抗体可实现与聚糖谱类似的变化,这表明体内观察到的变化是聚糖裂解的结果,而非抗体清除差异。这些结果证实抗体清除不受Fc聚糖结构的显著影响,并为人体中存在循环甘露糖苷酶活性提供了证据。